C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 19/02 (2006.01)
Patent
CA 2700351
The invention relates to a use of a CD20 antagonist in the manufacture of a medicament for treatment of an au-toimmune disease, wherein the medicament is for administration to a human patient in a single therapeutically effective intravenous (i.v.) infusion of said antagonist. The CD20 antagonist preferably is a CD20 antibody, and the autoimmune disease preferably is rheumatoid arthritis.
La présente invention concerne l'utilisation d'un antagoniste de CD20 dans la fabrication d'un médicament pour le traitement d'une maladie auto-immune, le médicament étant destiné à être administré à un patient humain par perfusion intraveineuse (IV) unique thérapeutiquement efficace dudit antagoniste. L'antagoniste de CD20 est de préférence un anticorps anti-CD20, et la maladie auto-immune est de préférence la polyarthrite rhumatoïde.
Borden Ladner Gervais Llp
F. Hoffmann-La Roche Ag
LandOfFree
Fixed single injection dosage for ocrelizumab (2h7) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fixed single injection dosage for ocrelizumab (2h7), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fixed single injection dosage for ocrelizumab (2h7) will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1877164